Malaria: Difference between revisions
From WikiDemocracy
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 179: | Line 179: | ||
[https://www.nature.com/articles/s43856-023-00373-y by Alisa Hamilton 13/10/23 communications medicine] | [https://www.nature.com/articles/s43856-023-00373-y by Alisa Hamilton 13/10/23 communications medicine] | ||
The emergence of antimalarial drug resistance poses a major threat to effective malaria treatment and control. This study aims to inform policymakers and vaccine developers on the potential of an effective malaria vaccine in reducing drug-resistant infections. | The emergence of antimalarial drug resistance poses a major threat to effective malaria treatment and control. This study aims to inform policymakers and vaccine developers on the potential of an effective malaria vaccine in reducing drug-resistant infections. | ||
=====Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial===== | |||
[https://www.sciencedirect.com/science/article/abs/pii/S0140673615607218 by RTS,S Clinical Trials Partnership ScienceDirect] | |||
The efficacy and safety of the RTS,S/AS01 candidate malaria vaccine during 18 months of follow-up have been published previously. Herein, we report the final results from the same trial, including the efficacy of a booster dose. | |||
